KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Operating Expenses (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Other Operating Expenses for 16 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 47.3% year-over-year to -$2.9 million, compared with a TTM value of -$2.6 million through Sep 2025, down 107.65%, and an annual FY2024 reading of $10.0 million, changed N/A over the prior year.
  • Other Operating Expenses was -$2.9 million for Q4 2025 at Biomarin Pharmaceutical, down from $4.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $111.9 million in Q4 2022 and bottomed at -$13.9 million in Q1 2023.
  • Average Other Operating Expenses over 5 years is $16.3 million, with a median of $1.8 million recorded in 2021.
  • Peak annual rise in Other Operating Expenses hit 22006.69% in 2022, while the deepest fall reached 261.04% in 2022.
  • Year by year, Other Operating Expenses stood at $11.8 million in 2021, then skyrocketed by 844.69% to $111.9 million in 2022, then plummeted by 83.63% to $18.3 million in 2023, then plummeted by 129.82% to -$5.5 million in 2024, then soared by 47.3% to -$2.9 million in 2025.
  • Business Quant data shows Other Operating Expenses for BMRN at -$2.9 million in Q4 2025, $4.8 million in Q2 2025, and -$2.0 million in Q1 2025.